Cofactor Genomics GTM brain

Cofactor Genomics develops RNA-based tests to help oncologists predict which cancer patients may respond to immunotherapy.

category

Predictive oncology diagnostics

market profile

  • text: Immunotherapy selection creates demand for better predictive biomarkers than single-analyte approaches.
  • text: OncoPrism is being studied across solid tumor indications through the PREDAPT clinical trial.

personas

  • title: Medical oncologist
    pains:
    • Choosing immunotherapy when existing biomarkers leave uncertainty about response
    • Need clinically validated evidence for a specific cancer and treatment setting
  • title: Molecular pathology or oncology laboratory director
    pains:
    • Coordinating tumor biopsy testing and sample workflows
    • Assessing clinical validation and reimbursement before adopting a new assay
  • title: Oncology clinical research director
    pains:
    • Recruiting suitable sites and samples for prospective biomarker studies
    • Demonstrating predictive performance across tumor types

icp

  • text: US cancer centers and health systems treating solid tumors with immunotherapy, especially sites with oncology and pathology services.
  • text: Academic and community oncology research sites able to contribute patients to retrospective or prospective biomarker studies.

message pillars

  • text: Use RNA to anticipate immunotherapy response.
  • text: Support patient matching with multidimensional models.
  • text: Build evidence through clinical collaborations.

objections

  • objection: Is this validated for my patient's specific cancer and treatment?
    response: Review indication-specific validation and study eligibility with the clinical team; avoid extrapolating results across cancers.
  • objection: Will the test be covered?
    response: Confirm patient-specific payer coverage and billing before ordering; Medicare coverage has been reported but does not establish universal coverage.

competitors

  • name: Caris Life Sciences
    why: Offers molecular profiling for precision oncology, an alternative source of treatment-relevant tumor data.
  • name: NeoGenomics
    why: Provides oncology molecular diagnostic testing to clinicians and laboratories.

influencers

  • name: Jarret Glasscock
    url: https://www.linkedin.com/in/jarretglasscock
    why: Founder and company scientific leader posting about OncoPrism milestones.

keywords

  • immunotherapy response prediction
  • RNA oncology biomarker
  • OncoPrism test
  • tumor immune profiling
  • head and neck cancer immunotherapy biomarker
  • NSCLC immunotherapy diagnostic

voice

  • clinical and evidence-oriented
  • patient-outcome focused
  • scientifically technical

signals

  • text: A cancer center is expanding immunotherapy services or seeking better patient selection for solid tumors.
  • text: A clinical research site is recruiting for immunotherapy biomarker studies.

pricing

model: unknown

motion

sales_led

channels

  • clinical research partnerships
  • medical conferences
  • publications
  • LinkedIn

confidence

medium

Founders

  • name: Dave Messina
    title: Founder/COO
    role: COO
    bio: Dr. Dave Messina has over 25 years of experience in healthcare and has been leading healthcare investments at Pioneer Fund since 2019. He has led 100+ deals including top portfolio companies like Gilgamesh ($1B exit to Abbvie) and Assort Health ($500M+ valuation). Previously he founded the RNA and machine learning company Cofactor Genomics (YC S15) and led it to national Medicare reimbursement. Dr. Messina also worked on the Human Genome Project.
  • name: Jarret Glasscock
    title: Founder/CTO
    role: CTO

Back to YC companies